Proteomics International and inVentiv Health Clinical have entered a collaboration agreement to offer full service biosimilar services on a global scale from structural and functional characterization to development of biosimilars and biologics. The collaboration aims to offer developers the ability to seamlessly transition from characterization to clinical trials.
Proteomics provides structural characterization and QC testing of proposed and referenced products with a suite of scientific instrumentation. These services will complement inVentiv Health’s bioanalytical capabilities from clinical development through commercialization in support of biosimilar development.
“We welcome the partnership with inVentiv as it represents a significant opportunity for us in furthering expansion into bio-generic markets,” said Dr. Richard Lipscombe, managing director of Proteomics International. “This collaboration will position both companies to better assist biosimilar and biologics developers in this emerging field and ever-changing regulatory environment.”
“The strengths of Proteomic International to demonstrate biosimilarity combined with inVentiv biologic clinical, commercial and consulting expertise is a winning solution for clients,” said Dr. George Scott, vice president, Bioanalytical Services for inVentiv Clinical. “Together we offer the full breadth and scope of an integrated roadmap of biosimilar development services to help navigate the complex regulatory and development landscape from early strategic planning, clinical trial conduct, and registration to commercialization.”